IL13 and neoplasm: In another study, Negera et al. explored the combinational therapy with simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) based on PEG-EXO-Dox can selectively target both tumor-associated macrophages and melanoma cells.